

CORRECTION

Open Access



Correction to: Accuracy of the tuberculosis point-of-care Alere determine lipoarabinomannan antigen diagnostic test using α -mannosidase treated and untreated urine in a cohort of people living with HIV in Guatemala

Juan Ignacio García^{1,2*†}, Johanna Meléndez^{3†}, Rosa Álvarez^{4†}, Carlos Mejía-Chew⁵, Holden V. Kelley², Sabeen Sidiki², Alejandra Castillo^{6,7}, Claudia Mazariegos^{6,7}, Cesar López-Téllez^{6,7}, Diana Forno⁸, Nancy Ayala⁹, Joan-Miquel Balada-Llasat¹⁰, Carlos Rodolfo Mejía-Villatoro³, Shu-Hua Wang¹¹, Jordi B. Torrelles^{2*} and Janet Ikeda^{6,7*}

Correction to: *AIDS Res Ther* (2020) 17:62

<https://doi.org/10.1186/s12981-020-00318-8>

In the original publication of this article [1], the authors were notified that there were some errors in Table 2 that were also present in the main text, specifically in the results section of the abstract, the overall sensitivity of the LAM-test of 56.1% with 95% CI of (43.3–68.3) should have been 62.7 with 95% CI of (49.1–75); the LAM-test sensitivity in PLWH with < 200 CD4 T cells/ μ l of 62.2% (95% CI 46.5–76.2) should have been of 71.8% with 95%

CI of (55.1–85), and the differences in sensitivity when comparing LAM-test results obtained from untreated vs. α -mannosidase treated urine had been deleted.

The sentence “the two participating UAIs using the Fischer exact test” in the statistical analysis sub-heading should have been “the LAM tests using the McNemar exact test”.

In the results section, the LAM-test sensitivity of 56.1% with 95% CI of (43.3–68.3) should have been 62.7 with 95% CI of (49.1–75), and the LAM-test sensitivity in PLWH with < 200 CD4 T cells/ μ l of 62.2% (95% CI 46.5–76.2) should have been of 71.8% with 95% CI of (55.1–85), the acronym “UIA” should have been “UAI”; the sentence “the defined gold standard composite” should have been “the defined reference standard”; the word “gold” has been eliminated; the sentence “composite gold referenced standard” should have been “composite reference standard”; the acronym “IAUs” should have been “UAI”, and the term “composite gold standard” should have been “composite reference standard”.

As a result, the authors have corrected Table 2. All sensitivity and specificity values have been corrected; the

The original article can be found online at <https://doi.org/10.1186/s12981-020-00318-8>.

[†]Juan Ignacio García, Johanna Meléndez and Rosa Álvarez: co-authors contributed equally to this work*Correspondence: juangarcia@txbiomed.org; JTorrelles@txbiomed.org; janet.m.ikeda@gmail.com

¹ Fundació Sida I Societat, Technical Advisor Unit (UAT), Escuintla National Hospital, Escuintla 5001, Guatemala

² Tuberculosis Group, Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA

⁶ Clínica de Atención Integral Dr. Isaac Cohen Alcahó, Hospital de Especialidad Dr. Robles, Quetzaltenango, Guatemala

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 2 Sensitivity and specificity comparisons of LAM test after α-mannosidase treatment of urine vs. LAM test by Site and CD4 values using a composite reference standard

All CD4 values	LAM after α-mannosidase treatment of urine		LAM alone		LAM after α-mannosidase treatment of urine		LAM alone		p value ^b
	Sensitivity (%) (95% CI)	Positive/N	Sensitivity (%) (95% CI)	Positive/N	Specificity (%) (95% CI)	Negative/N	Specificity (%) (95% CI)	Negative/N	
Both Sites ^a	62.7 (49.1-75)	37/59	62.7 (49.1-75)	37/59	87.9 (83-91.8)	204/232	87.1 (82.1-91.1)	202/232	0.414
Site 1	63.4 (46.9-77.9)	26/41	63.4 (46.9-77.9)	26/41	89 (84.1-92.8)	194/218	87.6 (82.5-91.7)	191/218	0.179
Site 2	61.1 (35.7-82.7)	11/18	61.1 (35.7-82.7)	11/18	71.4 (41.9-91.6)	10/14	78.6 (49.2-95.3)	11/14	0.317

CD4 values <200	LAM after α-mannosidase treatment of urine		LAM alone		LAM after α-mannosidase treatment of urine		LAM alone		p value ^b
	Sensitivity (%) (95% CI)	Positive/N	Sensitivity (%) (95% CI)	Positive/N	Specificity (%) (95% CI)	Negative/N	Specificity (%) (95% CI)	Negative/N	
Both Sites ^a	69.2 (52.4-83)	27/39	71.8 (55.1-85)	28/39	84.1 (76-90.3)	95/113	85 (77-91)	96/113	0.563
Site 1	59.3 (38.8-77.6)	16/27	63 (42.4-80.6)	17/27	86.3 (78-92.3)	88/102	86.3 (78-92.3)	88/102	1
Site 2	91.7 (61.5-99.8)	11/12	91.7 (61.5-99.8)	11/12	63.6 (30.8-89.1)	7/11	72.7 (39-94)	8/11	0.317

^a Site = Site 1 includes UAI 1 = "Dr. Isaac Cohen Alcah e" UAI and Rodolfo Robles Hospital. Site 2 includes UAI 2 = "Dr. Carlos Rodolfo Mej a" UAI and Roosevelt Hospital

^b McNemar exact test was used when comparing LAM test alone and LAM test after α-mannosidase treatment

McNemar exact test has replaced the Fischer exact test for p value calculations, and these p values have been corrected; the footnote has been modified to reflect these changes.

The authors apologize for any inconvenience.

Author details

¹Fundació Sida I Societat, Technical Advisor Unit (UAT), Escuintla National Hospital, Escuintla 5001, Guatemala. ²Tuberculosis Group, Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA. ³Unidad de Atención Integral del VIH E Infecciones Crónicas del Hospital Roosevelt "Dr. Carlos Rodolfo Mejía Villatoro", Guatemala City, Guatemala. ⁴Sección de Microbiología, Departamento de Laboratorios Clínicos, Hospital Roosevelt, Guatemala City, Guatemala. ⁵Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. ⁶Clinica de Atención Integral Dr. Isaac Cohen Alcahé, Hospital de Especialidad Dr. Robles, Quetzaltenango, Guatemala. ⁷Asociación de Investigación, Desarrollo Y Educación Integral (IDEI), Quetzaltenango, Guatemala. ⁸Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Central America Regional Office, Guatemala City, Guatemala. ⁹National Reference Laboratory, Amatitlan, Guatemala. ¹⁰Department of Pathology, The Ohio State University, Wexner Medical Center, Columbus, OH, USA. ¹¹Internal Medicine Department, Infectious Disease Division College of Medicine (COM), The Ohio State University (OSU), Columbus, OH 43210, USA.

Accepted: 17 August 2022

Published online: 20 October 2022

Reference

1. García JI, Meléndez J, Álvarez R, Mejía-Chew C, Kelley HV, Sidiki S, Castillo A, Mazariegos C, López-Téllez C, Forno D, Ayala N, Balada-Llasat J-M, Mejía-Villatoro CR, Wang S-H, Torrelles JB, Ikeda J. Accuracy of the tuberculosis point-of-care Alere determine lipoarabinomannan antigen diagnostic test using α -mannosidase treated and untreated urine in a cohort of people living with HIV in Guatemala. *AIDS Res Therapy*. 2020;17:62. <https://doi.org/10.1186/s12981-020-00318-8>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

